News
PPCB
1.770
+7.93%
0.130
Propanc Reports PRP Activity In Pancreatic Cancer Models, Files Combination Patent Application
NASDAQ · 6d ago
Propanc Biopharma, Inc. Receives Nasdaq Delisting Notice Over $1.00 Minimum Bid Price Requirement
NASDAQ · 6d ago
Propanc Biopharma reports preclinical PRP data
TipRanks · 11/02 14:12
Propanc Biopharma Advances Bioanalytical Development For PPC-001 Solid Tumours Trial
NASDAQ · 11/02 12:11
Weekly Report: what happened at PPCB last week (1026-1030)?
Weekly Report · 11/02 10:21
Propanc Biopharma Appeals Nasdaq Delisting After Bid Shortfall
TipRanks · 10/29 21:33
Propanc Biopharma targets February start for first-in-human cancer study
TipRanks · 10/28 13:20
Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation
Benzinga · 10/28 12:31
Propanc Biopharma announces new PRP preclinical data
TipRanks · 10/26 13:05
Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
Benzinga · 10/26 12:32
Weekly Report: what happened at PPCB last week (1019-1023)?
Weekly Report · 10/26 10:21
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
Benzinga · 10/22 12:32
Weekly Report: what happened at PPCB last week (1012-1016)?
Weekly Report · 10/19 10:21
Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27
NASDAQ · 10/19 00:11
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
Benzinga · 10/16 12:45
Propanc Biopharma announces new preclinical research from PRP programs
TipRanks · 10/16 12:40
Weekly Report: what happened at PPCB last week (1005-1009)?
Weekly Report · 10/12 10:26
Propanc Reports Positive Preclinical Pancreatic Cancer Data For PRP; Phase 1b Planned In Q1 2027
NASDAQ · 10/08 07:40
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
TipRanks · 10/07 13:20
Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock
Benzinga · 10/05 21:24
More
Webull provides a variety of real-time PPCB stock news. You can receive the latest news about Propanc Bio through multiple platforms. This information may help you make smarter investment decisions.
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.